Based on the DREAMM-7 and DREAMM-8 data, how would you incorporate belantamab mafadotin in your practice?

This is definitely top of mind with the publication of the DREAMM, BENEFIT, and IMROZ trials. Given my standard sequencing of myeloma treatments in non t(11;14) patients who are not clinical trial candidates, there is no longer a good time to incorporate a toxic BCMA antibody drug conjugate into the treatment algorithm for a patient that is not already refractory to a more effective BCMA-directed treatment, e.g. BCMA BsAb. If we could turn back the clock to 2022, my answer would have been differ...

In brief, I think the population of patients receiving belantamab in lines 2-4 and those who may receive CAR-T therapy in lines 2-4 are completely different. No overlap at all between these populations, since anyone who could get CAR-T really should get CAR-T! Deeper responses, longer responses, one-time infusions, no risk of ocular complications, and more.

I'd consider belantamab for any of the following populations:

1. Not a candidate for CAR-T therapy for clinical reasons - for example, cardiac d...